Related Experiment Video
Updated: Jun 24, 2026
07:22
Measuring the Motor Aspect of Cancer-Related Fatigue using a Handheld Dynamometer
Published on: February 20, 2020
[Fatigue in multiple sclerosis]
Ewa Dworzańska1, Krystyna Mitosek-Szewczyk, Zbigniew Stelmasiak
1Katedra i Klinika Neurologii, Uniwersytet Medyczny w Lublinie, Samodzielny Publiczny Szpital Kliniczny nr 4, ul. Jaczewskiego 8, 20-954 Lublin, Poland. cieckoewa@interia.pl
Neurologia I Neurochirurgia Polska
|April 9, 2009
Summary
Fatigue is a common symptom in multiple sclerosis (MS) impacting quality of life. Research is exploring immune and neuroendocrine factors, and management involves addressing secondary causes and therapies like modafinil.
Area of Science:
- Neurology
- Immunology
- Endocrinology
Context:
- Fatigue is a prevalent and debilitating symptom in multiple sclerosis (MS).
- It significantly reduces the quality of life for individuals with MS.
- The underlying mechanisms of MS-related fatigue are not fully understood.
Purpose:
- To explore the potential role of immune and neuroendocrine factors in MS fatigue.
- To outline the initial management steps for MS-related fatigue.
- To review assessment scales and therapeutic options for MS fatigue.
Summary:
- MS fatigue is characterized by apathy, exhaustion, and lack of energy.
- Potential causes include immune and neuroendocrine dysregulation.
- Management begins with excluding secondary causes and may involve pharmacological and non-pharmacological treatments.
- Scales like the Fatigue Severity Scale and Fatigue Impact Scale aid in assessment.
Impact:
- Improved understanding of MS fatigue mechanisms.
- Guidance for clinicians in managing MS-related fatigue.
- Potential for enhanced quality of life for MS patients through effective management strategies.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:21Fatigue
Fatigue occurs when materials rupture under repeated or fluctuating loads, even at stress levels far below their static breaking strength. It typically results in brittle failure, even for ductile materials. It is a critical consideration in designing machines and structural components subjected to repetitive or varying loads. The nature of these loadings can range from fluctuating loads like unbalanced pump impellers causing vibrations to repeatedly bending a thin steel rod wire back and forth...
01:24Muscle Recovery and Fatigue
Muscle fatigue refers to the decline in a muscle's ability to maintain the force of contraction after prolonged activity. It primarily stems from changes within muscle fibers. Even before experiencing muscle fatigue, one may feel tired and have the urge to stop the activity. This response, known as central fatigue, occurs due to changes in the central nervous system, namely the brain and spinal cord. While there is no single mechanism that induces fatigue, it may serve as a protective response...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...